Call Now

Human CD20 / MS4A1 Protein (TrxA Tag)

B1,Bp35,CD20,CVID5,LEU-16,MS4A1,MS4A2,S7

Catalog Number P11007-H34E
Organism Species Human
Host E. coli
Synonyms B1,Bp35,CD20,CVID5,LEU-16,MS4A1,MS4A2,S7
Molecular Weight The recombinant human MS4A1 consists 218 amino acids and predicts a molecular mass of 23.9 kDa.
predicted N Met
SDS-PAGE
Purity > 80 % as determined by SDS-PAGE.
Protein Construction A DNA sequence encoding the human MS4A1 (NP_068769.2) (Ile141-Ser188) was expressed with a TrxA tag at the N-terminus.
Bio-activity
Research Area Immunology |Adaptive Immunity |B Cell |B Cell CD Antigen
Formulation Lyophilized from sterile 50 mM Tris, 150 mM NaCl, 1 mM EDTA, pH 8.0.
1. Normally 5 % - 8 % trehalose and mannitol are added as protectants before lyophilization. Specific concentrations are included in the hardcopy of COA.
Background CD20 (membrane-spanning 4-domains, subfamily A, member 1), also known as MS4A1, is a member of the membrane-spanning 4A gene family. Members of this nascent protein family are characterized by common structural features and similar intron/exon splice boundaries and display unique expression patterns among hematopoietic cells and nonlymphoid tissues. CD20 / MS4A1 is expressed on all stages of B cell development except the first and last. CD20 / MS4A1 is present from pre-pre B cells through memory cells, but not on either pro-B cells or plasma cells. It is a B-lymphocyte surface molecule which plays a role in the development and differentiation of B-cells into plasma cells. CD20 / MS4A1may be involved in the regulation of B-cell activation and proliferation. Defects in CD20 / MS4A1 are the cause of immunodeficiency common variable type 5(CVID5). CVID5 is a primary immunodeficiency characterized by antibody deficiency, hypogammaglobulinemia, recurrent bacterial infections and an inability to mount an antibody response to antigen. The defect results from a failure of B-cell differentiation and impaired secretion of immunoglobulins; the numbers of circulating B-cells is usually in the normal range, but can be low.
Reference
  • Tedder TF, et al. (1988) Isolation and structure of a cDNA encoding the B1 (CD20) cell-surface antigen of human B lymphocytes. Proc Natl Acad Sci. 85(1): 208-12.
  • Cragg MS, et al. (2005) The biology of CD20 and its potential as a target for mAb therapy. Curr Dir Autoimmun. 8: 140-74..
  • Polyak MJ, et al. (2003) A cholesterol-dependent CD20 epitope detected by the FMC7 antibody. Leukemia. 17(7): 1384-9.